Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

Executive Summary

Shares in UK company Indivior jumped by more than 12% on Aug. 17 on the LSE on the back of top-line Phase III data for its monthly buprenorphine depot for opioid addiction, and confirmation that a Q4 2017 US approval is still within its sights.


Related Content

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market
Ten Approvals To Look Out For In Q4
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts